Feb 24, 2021 / 01:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the [Status] Clinical Update -- I'm sorry, the Salarius Clinical Update Call.
At this time, all participants are in a listen only mode. After the speakers' presentation, we will have a question-and-answer session. (Operator Instructions).
At this time, I would like to turn the conference over today to Mr. Jason Rando. Please go ahead, sir.
Jason Rando - Tiberend Strategic Advisors, Inc. - EVP & COO
Good morning, everyone, and thank you for joining today's conference call. Earlier this morning Salarius Pharmaceuticals issued a press release announcing the initiation of the expansion phase of its ongoing Phase 1/2 Clinical Trial for Seclidemstat in relapsed and refractory Ewing sarcoma and Ewing-related sarcoma patients. The press release can be found in the news section of the salariuspharma.com.
Before beginning today's call, I would like to make the following statement. Today, we'll be making forward-looking statements about future expectations, plans, events and
Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers